Janssen Patent Reduces Cardiovascular Events in Type II Diabetes Patients

The European Patent Office published Patent EP3638250A1 granting Janssen Pharmaceutica NV exclusive rights to a method for reducing or preventing cardiovascular events in Type II diabetes mellitus patients. The patent specifies pharmaceutical compositions and therapeutic methods using compounds classified under A61K 31/7042 targeting A61P 9/00 (cardiovascular preparations). The designation covers all European Patent Convention member states.

For pharmaceutical companies developing diabetes treatments with cardiovascular benefits, this patent establishes intellectual property barriers requiring careful freedom-to-operate analysis. Competitors in the cardiovascular-diabetes therapeutic space should monitor Janssen's patent portfolio and consider licensing discussions or alternative formulation approaches.